Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension
Barbara O Meyrick, David B Friedman, D Dean Billheimer, Joy D Cogan, Melissa A Prince, John A Phillips 3rd, James E Loyd, Barbara O Meyrick, David B Friedman, D Dean Billheimer, Joy D Cogan, Melissa A Prince, John A Phillips 3rd, James E Loyd
Abstract
Rationale: Not all family members with BMPR2 mutations develop pulmonary arterial hypertension (PAH), implying that additional modifier genes or proteins are necessary for full expression of the disease.
Objectives: To determine whether protein expression is altered in patients with familial PAH (FPAH) compared with obligate carriers and nondiseased control subjects.
Methods: Protein extracts from transformed blood lymphocytes from four patients with FPAH, three obligate carriers, and three married-in control subjects from one family with a known BMPR2 mutation (exon 3 T354G) were labeled with either Cy3 or Cy5. Cy3/5 pairs were separated by standard two-dimensional differential gel electrophoresis using a Cy2-labeled internal standard of all patient samples. Log volume ratios were analyzed using a linear mixed-effects model. Proteins were identified by matrix-assisted laser desorption ionization, time-of-flight mass spectrometry (MALDI-TOF MS) and tandem TOF/TOF MS/MS.
Measurements and main results: Hierarchical clustering, heat-map, and principal components analysis revealed marked changes in protein expression in patients with FPAH when compared with obligate carriers. Significant changes were apparent in expression of 16 proteins (P < 0.05) when affected patients were compared with obligates: nine showed a significant increase and seven showed a significant reduction.
Conclusions: A series of novel proteins with altered expression were found that could distinguish affected patients from obligate carriers and married-in controls in a single family with a BMPR2 mutation. These differences provide new information highlighting proteins that may be involved in the mechanism(s) that differentiates those individuals with a BMPR2 mutation who develop FPAH from those who do not.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f1.jpg)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f2.jpg)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f3.jpg)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f4.jpg)
![Figure 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f5.jpg)
![Figure 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2176118/bin/AJRCCM177199f6.jpg)
Source: PubMed